23-apr-2025
Novo Nordisk will face competition in the obisitas and diabetes space. Regulation and insurances may impact its growth. However if Novo Nordisk will be succesfull in the area of development of medicines in the cardiovascular and Gene & Stem CellTherapies they will differentiate from others letting their moat grow!
Most important is their overall growth potential. It will be slow but it will grow (normal for a large CAP company) which is fundamental! Hopefully they will increase their dividend to attrack investors.
It's shareprice may come down to around $50 (support line mid 2022). After it's fall momentum will get better. At this moment signals might indicate it's fall is going to be stopped. Let's follow it's shareprice closely.
How well do narratives help inform your perspective?
Disclaimer
The user Silvester holds no position in NYSE:NVO. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
